BR112015022202A2 - compostos substituídos de naftiridina e quinolina como inibidores da mao - Google Patents

compostos substituídos de naftiridina e quinolina como inibidores da mao

Info

Publication number
BR112015022202A2
BR112015022202A2 BR112015022202A BR112015022202A BR112015022202A2 BR 112015022202 A2 BR112015022202 A2 BR 112015022202A2 BR 112015022202 A BR112015022202 A BR 112015022202A BR 112015022202 A BR112015022202 A BR 112015022202A BR 112015022202 A2 BR112015022202 A2 BR 112015022202A2
Authority
BR
Brazil
Prior art keywords
disorders
cognitive
inhibitors
quinoline compounds
efficiency
Prior art date
Application number
BR112015022202A
Other languages
English (en)
Inventor
Kaplan Alan
Pratt Benjamin
Mak Chi-Ching
Sengupta Dipanjan
Freestone Graeme
Basinger Jillian
Valdez Lino
Gupta Varsha
Santora Vincent
Original Assignee
Dart Neuroscience Cayman Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dart Neuroscience Cayman Ltd filed Critical Dart Neuroscience Cayman Ltd
Publication of BR112015022202A2 publication Critical patent/BR112015022202A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
    • C07D215/60—N-oxides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

“compostos substituídos de naftiridina e quinolina como inibidores da mao” resumo a presente invenção propõe uma entidade química de fórmula (i), onde r1, r2, r3, y e n têm qualquer um dos valores descritos neste documento, e composições que compreendem as referidas entidades químicas; métodos para produzi-las; e seu uso em uma ampla variedade de métodos, inclusive estudos metabólicos de cinéticos de reação, técnicas de detecção e imagiologia e tratamentos radioativos; e terapias, incluindo inibir a mao e, seletivamente, a mao-b, intensificar a plasticidade neural, tratar transtornos neurológicos, oferecer neuroproteção, tratar uma debilidade cognitiva ou motora associada a um transtorno do snc, intensificar a eficiência de treinamentos cognitivos e motores, oferecer neurorrecuperação e neurorreabilitação, intensificar a eficiência de protocolos de treinamento de animais não humanos e tratar transtornos periféricos (inclusive obesidade, diabetes e transtornos cardiometabólicos) e suas comorbidades associadas. 20/1 1/1
BR112015022202A 2013-03-14 2014-03-05 compostos substituídos de naftiridina e quinolina como inibidores da mao BR112015022202A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361785872P 2013-03-14 2013-03-14
PCT/US2014/020881 WO2014158916A1 (en) 2013-03-14 2014-03-05 Substituted naphthyridine and quinoline compounds as mao inhibitors

Publications (1)

Publication Number Publication Date
BR112015022202A2 true BR112015022202A2 (pt) 2017-07-18

Family

ID=51530146

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015022202A BR112015022202A2 (pt) 2013-03-14 2014-03-05 compostos substituídos de naftiridina e quinolina como inibidores da mao

Country Status (16)

Country Link
US (4) US9102674B2 (pt)
EP (1) EP2970125B1 (pt)
JP (1) JP6346658B2 (pt)
KR (1) KR20150127172A (pt)
CN (1) CN105143190B (pt)
AU (1) AU2014241759B2 (pt)
BR (1) BR112015022202A2 (pt)
CA (1) CA2895287A1 (pt)
HK (1) HK1220185A1 (pt)
IL (1) IL240805B (pt)
MX (1) MX2015011144A (pt)
NZ (1) NZ711598A (pt)
RU (1) RU2661156C2 (pt)
SG (1) SG11201504704TA (pt)
TW (1) TWI657078B (pt)
WO (1) WO2014158916A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6346658B2 (ja) 2013-03-14 2018-06-20 ダート・ニューロサイエンス・（ケイマン）・リミテッド Ｍａｏ阻害剤としての置換ナフチリジン及びキノリン化合物
BR112017005376A2 (pt) * 2014-09-17 2018-08-14 Dart Neuroscience Cayman Ltd inibidores de mao-b e reabilitação.
CN104496998B (zh) * 2014-12-15 2017-07-11 陕西嘉禾生物科技股份有限公司 一种1′‑苄基‑2′‑酮‑5′，7′，8′‑三氢‑螺‑[1，3‑二氧五环‑2]‑喹啉的制备方法
WO2016125187A1 (en) 2015-02-03 2016-08-11 Council Of Scientific & Industrial Research Novel quinoline derivatives and preparation thereof
WO2016179432A2 (en) 2015-05-05 2016-11-10 Dart Neuroscience, Llc Systems and methods for cognitive testing
CN108602826A (zh) * 2016-02-04 2018-09-28 默克专利有限公司 作为半导体的[1,5]二氮杂萘化合物和聚合物
US11370775B2 (en) * 2016-09-14 2022-06-28 Yufeng Jane Tseng Substituted benzimidazole derivatives as D-amino acid oxidase (DAAO) inhibitors
WO2018064465A1 (en) * 2016-09-29 2018-04-05 The Regents Of The University Of California Compounds for increasing neural plasticity
CN107216331B (zh) * 2017-07-07 2019-06-18 华南理工大学 一种四氢萘啶并四氢喹唑啉衍生物及其合成方法和应用
KR102005019B1 (ko) * 2018-04-04 2019-07-31 한국과학기술연구원 뇌졸중의 예방 및 치료용 조성물
CN108658977A (zh) * 2018-04-12 2018-10-16 苏州康润医药有限公司 一种7-溴-1,5-萘啶-3-甲酸的合成方法
MX2021010198A (es) 2019-02-27 2021-09-21 Univ California Indoles n-sustituidos y otros heterociclos para el tratamiento de trastornos cerebrales.
KR20210134689A (ko) 2019-02-27 2021-11-10 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 뇌 장애를 치료하기 위한 아제피노-인돌 및 다른 헤테로사이클
CN112939952A (zh) * 2021-02-02 2021-06-11 深圳市第二人民医院(深圳市转化医学研究院) 一种3-羟基查尔酮衍生物及其用途
CN112898276A (zh) * 2021-02-02 2021-06-04 深圳市第二人民医院(深圳市转化医学研究院) 一种查尔酮衍生物及其用途
CN114437068A (zh) * 2022-02-21 2022-05-06 深圳市儿童医院 一种萘啶衍生物及其作为单胺氧化酶抑制剂的用途

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1138540A (en) * 1966-09-19 1969-01-01 Ici Ltd Quinoline derivatives
SU550385A1 (ru) * 1975-09-22 1977-03-15 Институт Биологической И Медицинской Химии Амн Ссср 8-( -Метил - -пропинил-2)-аминометилхинолин как ингибитор моноаминоксидазы и способ его получени
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
JPH04295470A (ja) 1991-03-22 1992-10-20 Wakamoto Pharmaceut Co Ltd モノアミンオキシダーゼ−ｂ酵素阻害活性を有する１，２，４−オキサジアゾール誘導体及びその製造法
US5510361A (en) 1994-10-20 1996-04-23 The Procter & Gamble Company Di-tert-butylphenol compounds with heterocyclic moiety, useful as anti-inflammatory agents
ATE399545T1 (de) 1996-11-08 2008-07-15 Nippon Chemiphar Co Mittel zur verringerung der eigeweidefette
EP0994095A1 (en) 1996-12-24 2000-04-19 Nippon Chemiphar Co., Ltd. Propionic acid derivatives
DK1355669T3 (da) 2000-08-10 2011-11-21 Cold Spring Harbor Lab Forbedret kognitiv træning
US7868015B2 (en) 2000-08-10 2011-01-11 Cold Spring Harbor Laboratory Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit
US9931318B2 (en) 2003-04-08 2018-04-03 Dart Neuroscience (Cayman) Ltd. Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
JP2002322163A (ja) * 2001-04-20 2002-11-08 Sumitomo Pharmaceut Co Ltd ピペラジン誘導体
FR2834640B1 (fr) 2002-01-11 2004-09-24 Lipha Composition pharmaceutique comprenant une glitazone et un acide 4-oxobutanoique et son utilisation pour traiter le diabete
WO2003062233A1 (fr) 2002-01-18 2003-07-31 Yamanouchi Pharmaceutical Co., Ltd. Derive de 2-acylaminothiazole et son sel
US6761089B2 (en) 2002-07-01 2004-07-13 Proqual, Llc Tool for removing screws with damaged heads
TWI286132B (en) 2002-09-20 2007-09-01 Hoffmann La Roche 4-pyrrolidino-phenyl-benzyl ether derivatives
EP1643352A4 (en) 2003-07-02 2009-03-04 Satoshi Yamatake DATABASE SYSTEM
CA2543287A1 (en) * 2003-10-23 2005-05-06 F.Hoffmann-La Roche Ag Benzazepine derivatives as mao-b inhibitors
US7501528B2 (en) 2005-03-15 2009-03-10 Hoffmann-La Roche Inc. Method for preparing enantiomerically pure 4-pyrrolidino phenylbenzyl ether derivatives
KR20070121028A (ko) 2005-03-29 2007-12-26 뉴론 파마슈티칼즈 에스. 피. 에이. 치환된 아미노알킬- 및 아미도알킬-벤조피란 유도체
US8138209B2 (en) 2005-07-13 2012-03-20 Jenrin Discovery, Inc. Substituted picolinamides as MAO-B inhibitors useful for treating obesity
EP2465850B1 (en) 2006-02-28 2016-11-23 Dart Neuroscience (Cayman) Ltd Therapeutic compounds
EP2152275A4 (en) 2007-05-15 2011-08-03 Helicon Therapeutics Inc METHODS OF IDENTIFYING GENES INVOLVED IN MEMORY FORMATION USING SMALL INTERFERING RNA (SIARN)
AU2008293542B9 (en) 2007-08-27 2014-08-07 Dart Neuroscience (Cayman) Ltd. Therapeutic isoxazole compounds
AU2008357946B2 (en) * 2008-06-20 2013-06-20 Rottapharm Biotech S.R.L. 6-1H-imidazo-quinazoline and quinolines derivatives, new MAO inhibitors and imidazoline receptor ligands
US20110212031A1 (en) 2008-10-31 2011-09-01 Cyrille Sur Novel substituted azabenzoxazoles
ES2343347B2 (es) 2009-01-27 2011-12-07 Universidade De Santiago De Compostela Uso de derivados de 3-fenilcumarinas 6-sustituidas y preparacion de nuevos derivados.
KR101220182B1 (ko) 2009-02-25 2013-01-11 에스케이바이오팜 주식회사 치환된 아졸 유도체 화합물, 이를 포함하는 약제학적 조성물 및 이를 이용한 파킨슨씨 병 치료방법
JP6346658B2 (ja) 2013-03-14 2018-06-20 ダート・ニューロサイエンス・（ケイマン）・リミテッド Ｍａｏ阻害剤としての置換ナフチリジン及びキノリン化合物

Also Published As

Publication number Publication date
EP2970125A4 (en) 2016-07-27
CN105143190B (zh) 2017-08-18
WO2014158916A1 (en) 2014-10-02
HK1220185A1 (zh) 2017-04-28
IL240805A0 (en) 2015-10-29
US20160074377A1 (en) 2016-03-17
NZ711598A (en) 2016-09-30
TW201506012A (zh) 2015-02-16
SG11201504704TA (en) 2015-07-30
US20140275548A1 (en) 2014-09-18
AU2014241759A1 (en) 2015-09-17
AU2014241759B2 (en) 2017-10-19
US9675605B2 (en) 2017-06-13
CA2895287A1 (en) 2014-10-02
MX2015011144A (es) 2016-02-09
US9150572B2 (en) 2015-10-06
US20170312263A1 (en) 2017-11-02
RU2015137619A (ru) 2017-04-20
JP6346658B2 (ja) 2018-06-20
JP2016512256A (ja) 2016-04-25
CN105143190A (zh) 2015-12-09
US9956213B2 (en) 2018-05-01
EP2970125B1 (en) 2018-07-18
TWI657078B (zh) 2019-04-21
RU2661156C2 (ru) 2018-07-12
US20140315944A1 (en) 2014-10-23
IL240805B (en) 2018-07-31
US9102674B2 (en) 2015-08-11
KR20150127172A (ko) 2015-11-16
EP2970125A1 (en) 2016-01-20

Similar Documents

Publication Publication Date Title
BR112015022202A2 (pt) compostos substituídos de naftiridina e quinolina como inibidores da mao
BR112015022474A8 (pt) compostos de piridina e pirazina substituídos como inibidores de pde4.
EA201591340A1 (ru) Модулятор андрогенного рецептора и его применения
BR112017007767A2 (pt) canabidiol para uso, método para tratar um paciente que sofre de complexo esclerose tuberosa, e, composição.
BR112013002012A2 (pt) métodos e composições para terapia de câncer de fígado
EA201691619A1 (ru) Конденсированные гетероциклические соединения
WO2015173633A3 (en) Hdl therapy markers
WO2013192274A3 (en) Diagnostic and treatment methods in subjects having or at risk of developing resistance to cancer therapy
PE20150669A1 (es) Derivados de benzamida para la inhibicion de la actividad de abl1, abl2 y bcr-abl1
EA029939B8 (ru) Человеческие связывающие молекулы, обладающие способностью нейтрализовывать вирус гриппа h3n2, и их применение
EA201491221A1 (ru) Новые молекулы, ингибирующие jnk, для лечения различных болезней
EA201590703A1 (ru) Ингибиторы mek при лечении вирусных заболеваний
EA201690007A1 (ru) Соединения, ингибирующие металлоферменты
IN2015DN00438A (pt)
BR112017003571A2 (pt) terapia combinada
EA201790207A8 (ru) Новые замещенные пиримидиновые соединения
EA201301336A1 (ru) Лечение рака комбинацией молекул днк, имитирующих двухнитевые разрывы, и гипертермии
WO2014205266A3 (en) Compositions and methods for detecting and treating glioblastoma
EA201792096A3 (ru) РАППγ АГОНИСТЫ ДЛЯ ЛЕЧЕНИЯ РАССЕЯННОГО СКЛЕРОЗА
BR112015019873A2 (pt) inibidores macrocíclicos da lrrk2 cinase
MY189342A (en) Treatment and prevention of the common cold using povidone-iodine
BR112016010159A2 (pt) usos de um conjunto de ácidos nucleicos e de um chip de microarranjo, chip de microarranjo, métodos para detecção de patógenos e/ou microrganismos benéficos em uma amostra orgânica e de tratamento de uma relva doente, e, kit
FI20115165A0 (fi) Terapeuttisia ja diagnostisia menetelmiä
EA201590884A1 (ru) Способы лечения заболеваний печени
BR112016014182A2 (pt) Composições de ácidos graxos ômega 3 para tratar doenças que envolvem danos ao sistema nervoso

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time